MedTrace Logo

SGLT2 Inhibition in Hemodialysis

NCT05179668 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2026-03-03

No results posted yet for this study

Summary

Dapagliflozin will be compared with placebo to evaluate its effects on cardiac structure and safety in patients with kidney failure receiving maintenance hemodialysis.

Conditions

Interventions

DRUG

Dapagliflozin 10 MG

administered orally once daily

DRUG

Placebo

administered orally once daily

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Manfred Hecking, MD, PhD · Medical University of Vienna, Department of Medicine III, Division of Nephrology and Dialysis

  • Thomas A Zelniker, MD, MSc · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2025-07-11
Completion
2026-02-28

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05179668 on ClinicalTrials.gov